Ask AI
ProCE Banner Activity

Phase III N0147 Substudy: Relationship Between Postoperative ctDNA and Patient Outcomes After FOLFOX-Based Adjuvant Therapy for Stage III Colon Cancer

Conference Coverage
Slideset

Substudy of the phase III Alliance N0147 trial suggests that ctDNA detected in postoperative samples is prognostic for worse disease-free survival and overall survival in patients with stage III colon cancer receiving FOLFOX-based adjuvant therapy.

Released: June 09, 2025

Expiration: December 08, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Daiichi Sankyo, Inc. and Genentech, a member of the Roche Group.

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group